Helus Pharma Strengthens Leadership with Key Hires and Scientific Advisor

Helus Pharma, the commercial operating name of Cybin Inc., has announced two key appointments to bolster its leadership as it advances its pipeline of novel serotonergic agonists (NSAs) for mental health conditions. Regina Donohue joins as chief people officer, bringing extensive experience from her previous role as chief human resources officer at Intra-Cellular, where she scaled the company to over 1,000 employees before its acquisition by Johnson & Johnson. Suresh Durgam, M.D., has been appointed to the Scientific Advisory Board, leveraging over two decades of CNS drug development expertise, including his tenure as executive vice president and chief medical officer at Intra-Cellular, where he contributed to FDA approvals for CAPLYTA. CEO Michael Halstead emphasized that these additions strengthen the company's organizational and scientific capabilities as it moves toward commercialization.

Helus Pharma is focused on developing proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity, targeting major depressive disorder and generalized anxiety disorder. The company's lead candidate, HLP003, is in Phase 3 trials for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the FDA, while HLP004 is in Phase 2 for generalized anxiety disorder. With operations in Canada, the U.S., the UK, and Ireland, Helus Pharma aims to address significant unmet needs in mental health treatment. For more details, visit the full press release at https://ibn.fm/Z7rgQ and explore company updates at www.helus.com. The company's newsroom is available at https://ibn.fm/HELP. This announcement was distributed by InvestorWire, a platform for advanced press release syndication, as part of its Dynamic Brand Portfolio.